GIT 27 is an orally active, isoxazole compound that exhibits various immunomodulatory properties both in vitro and in preclinical in vivo models of autoimmune diseases by inhibiting inflammatory antigen presentation. It has been shown to target macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, macrophage migration inhibitory factor, and inducible nitric oxide synthase-mediated nitric oxide generation in both pancreatic islets and peripheral compartments. GIT 27 can also prevent IL-1β/interferon-γ-induced pancreatic islet death in vitro at 10 μg/ml and reduce the cumulative incidence of diabetes and insulitis in a mouse model of type 1 diabetes at 20 mg/kg.
